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Bovine leukemia virus (BLV) proviral latency represents a
viral strategy to escape thehost immune systemandallow tumor
development. Besides the previously demonstrated role of his-
tone deacetylation in the epigenetic repression of BLV expres-
sion,we showedhere that BLVpromoter activitywas induced by
several DNAmethylation inhibitors (such as 5-aza-2-deoxycy-
tidine) and that overexpressed DNMT1 and DNMT3A, but not
DNMT3B, down-regulatedBLVpromoter activity. Importantly,
cytosine hypermethylation in the 5-long terminal repeat (LTR)
U3 and R regions was associated with true latency in the lym-
phoma-derivedB-cell line L267 but notwith defective latency in
YR2 cells. Moreover, the virus-encoded transactivator TaxBLV
decreased DNA methyltransferase expression levels, which
could explain the lower level of cytosine methylation observed
in the L267LTaxSN 5-LTR compared with the L267 5-LTR.
Interestingly,DNAmethylation inhibitors andTaxBLV synergis-
tically activated BLV promoter transcriptional activity in a
cAMP-responsive element (CRE)-dependent manner. Mecha-
nistically, methylation at the 154 or 129 CpG position
(relative to the transcription start site) impaired in vitro
binding of CRE-binding protein (CREB) transcription factors
to their respective CRE sites. Methylation at129 CpG alone
was sufficient to decrease BLV promoter-driven reporter
gene expression by 2-fold. We demonstrated in vivo the
recruitment of CREB/CRE modulator (CREM) and to a lesser
extent activating transcription factor-1 (ATF-1) to the
hypomethylated CRE region of the YR2 5-LTR, whereas we
detected no CREB/CREM/ATF recruitment to the hyper-
methylated corresponding region in the L267 cells. Alto-
gether, these findings suggest that site-specific DNA methyl-
ation of the BLV promoter represses viral transcription by
directly inhibiting transcription factor binding, thereby con-
tributing to true proviral latency.
Bovine leukemia virus (BLV)12 is a B-lymphotropic onco-
genic retrovirus that infects cattle and is associated with enzo-
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otic bovine leucosis, a neoplastic proliferation of B cells (1–5).
BLV is structurally and biologically closely related to human
T-lymphotropic viruses HTLV-I and HTLV-II (4, 6). The
majority of BLV-infected cattle are asymptomatic carriers of
the virus. Only about 30% of BLV-infected animals develop a
preneoplastic condition termed persistent lymphocytosis,
with 2–5% developing B-cell leukemia and/or lymphoma
after a long latency period (7). The virus can be inoculated
experimentally into sheep, in which the disease appears ear-
lier and with higher frequencies, providing a helpful model
for understanding BLV and HTLV-induced leukemogenesis.
BLV infection is characterized by viral latency in a large
majority of infected cells and by the absence of viremia.
These features are thought to be due to the transcriptional
repression of viral expression in vivo (8–11). Latency is likely
to be a viral strategy to escape the host immune response and
allow tumor development.
The BLV transcriptional promoter is located in the 5-long
terminal repeat (5-LTR) and is composed of the U3, R, and U5
regions. Transcription initiates at the U3–R junction of the
5-LTR. BLV gene expression is induced at the transcriptional
level by the virus-encoded transactivator TaxBLV (12, 13).
Transactivation by TaxBLV requires the presence of three 21-bp
enhancer elements (called Tax-responsive elements (TxREs))
located in the U3 region of the 5-LTR (12, 14). Each TxRE
contains a core octanucleotide sequence corresponding to an
imperfectly conserved cyclic AMP-responsive element (CRE),
which binds cellular transcription factors: the CRE-binding
protein (CREB), the CRE-modulator  isoform (CREM), and
activating transcription factor-1 and -2 (ATF-1 and ATF-2)
(14–17). Besides the imperfect CRE consensus, each TxRE also
contains an E-box sequence, which overlaps each of the three
CRE motifs (4, 18). A PU.1/Spi-B site (19) and a glucocorticoid
responsive-element (20–23) are also present in the U3 region.
In addition, BLV expression is regulated by LTR sequences
located downstream of the transcription initiation site: an
upstream stimulatory factor-binding site in the R region (24)
and an interferon regulatory factor-binding site in the U5
region (25).
During retroviral infection, the RNA viral genome is retro-
transcribed into double-stranded DNA, which becomes inte-
grated into the host genome and is organized into chromatin as
all cellular genes. This chromatin environment is likely to be a
key parameter for the control of viral gene expression because
transcriptional activation by cellular or viral trans-acting fac-
tors is dependent on chromatin accessibility. BLV expression
is controlled by chromatin structure. Indeed, our laboratory
reported previously that histone acetylation is an important
epigenetic modification for TaxBLV-dependent and -indepen-
dent viral transcriptional regulation (26–29). BLV promoter
activity is induced by deacetylase (HDAC) inhibitors, and this is
correlated with an increased histone-4 acetylation at the viral
promoter (27). Our laboratory has also demonstrated that
HDAC inhibitors and TaxBLV synergistically activate BLV pro-
moter transcriptional activity in a CRE- and CREB-dependent
manner. This synergism is mediated by an HDAC inhibitor
indirect action that requires de novo protein synthesis and that
increases the level of CREB/ATF bound to the BLV promoter
(28).
To further investigate the role of chromatin structure in the
control of BLV gene expression, we studied in this report the
involvement of another epigenetic modification, DNA methy-
lation, in BLV gene expression regulation. The enzymes that
establish and maintain specific DNA methylation patterns
include the de novo DNA methyltransferases DNMT3A and
DNMT3B and the maintenance DNA methyltransferase
DNMT1 (30, 31). In mammalian cells, DNA methylation
occurs predominantly at cytosines in CpG dinucleotides of
transcriptional regulatory regions and is generally associated
with gene silencing, either directly by inhibiting the binding of
transcription factors to their recognition sequences or indi-
rectly by preventing transcription factors from accessing their
target sites through attachment of methyl-CpG-binding pro-
teins, which “read” DNA methylation patterns. These proteins
(MeCPs) recruit histone deacetylases and histonemethyltrans-
ferases, thereby resulting in formation of a closed repressive
chromatin structure (31, 32). Here, we have demonstrated
that DNA cytosine hypermethylation is associated with BLV
postintegration latency in a lymphoma-derived B-cell line,
L267. Mechanistically, site-specific methylation in BLV pro-
moter CRE elements inhibits CREB/CREM/ATF-1 in vitro
binding and decreases by 2-fold BLV LTR-driven transcription.
Importantly, by chromatin immunoprecipitation (ChIP) assays,
we have demonstrated in vivo the recruitment of the transcrip-
tion factors CREB and CREM, and to a lesser extent ATF-1, to
the hypomethylatedCRE region of the YR2 5-LTR,whereaswe
detected no CREB/CREM/ATF recruitment to the hyperm-
ethylated corresponding region in the L267 cells. Interestingly,
we show that TaxBLV protein decreases the expression levels of
DNMT1, DNMT3A, and DNMT3B, which could, at least in
part, explain the lower level of DNA methylation observed in
the L267LTaxSN 5-LTR compared with the L267 5-LTR. These
results indicate that DNA methylation contributes to proviral
latency, a viral strategy to escape host immune response and
allow tumor development.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture—The Raji cell line, a human
B-lymphoid Epstein-Barr virus-positive cell line derived from
a Burkitt’s lymphoma, and the Epstein-Barr virus-negative
B-lymphoid cell line DG75 were maintained in RPMI 1640-
Glutamax I medium (Invitrogen) supplemented with 10% fetal
bovine serum, 50 g of streptomycin/ml and 50 units of peni-
cillin/ml. The human epithelial HeLa cell line is derived from a
cervical carcinoma and is transformed by human papillomavi-
rus type 18. HeLa cells were cultured in Dulbecco’s modified
Eagle’s-Glutamax I medium (Invitrogen) supplemented with
5% fetal bovine serum, 50g of streptomycin/ml and 50 units of
penicillin/ml. L267 is a clonal lymphoma-derived B-cell line
established from a BLV-infected sheep (S267) injected with
naked proviral DNA of an infectious BLV variant described
previously (33–35). The tumor-derived L267 provirus displays
a wild-type sequence that is identical to the infectious provirus
used for sheep S267 inoculation (34, 35). The L267LTaxSN cell
line results from the transduction of native L267 with the
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pLTaxSN retroviral vector expressing the tax cDNA following
cocultivation with the PG13LTaxSN producer cell line and G418
selection of transduced cells (34, 36). L267 andL267LTaxSNwere
maintained in Opti-MEMmedium (Invitrogen) supplemented
with 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM
glutamine, non-essential amino acids, and 100 g of kanamy-
cin. YR2 is a cloned B-lymphoid cell line established from
peripheral blood lymphocytes isolated from a BLV-infected
sheep (10, 36, 37). YR2 cells were maintained in Opti-MEM-
Glutamax I medium (Invitrogen) supplemented with 10% fetal
bovine serum, 50 g of streptomycin/ml, and 50 units of peni-
cillin/ml. All cells were grown at 37 °C in an atmosphere of 5%
CO2.
Transient Transfection and Luciferase Assays—Raji and
DG75 cells were transfected using the DEAE-dextran proce-
dure as described previously (38). At 22 h after transfection, the
cells were mock-treated or treated with increasing concentra-
tions of procaine (Sigma), procainamide (Sigma), 5-aza-2-de-
oxycytidine (Sigma), or zebularine (Calbiochem) as indicated.
At 72 h after induction, the cells were lysed and assayed for
luciferase activity (Promega). Luciferase activitieswere normal-
ized with respect to protein concentrations using the deter-
gent-compatible protein assay (Bio-Rad). HeLa cells were
transfected using FuGENETM 6 (Roche Applied Science) as
described previously (24). All transfection mixtures contained
pRL-TK (50 ng), inwhich a cDNAencodingRenilla luciferase is
under the control of the herpes simplex virus thymidine kinase
promoter region and which is used as an internal control for
transfection efficiency. At 48 h posttransfection, luciferase
activities (firefly and Renilla) were measured in cell lysates by
using the dual luciferase reporter assay system (Promega).
Western Blotting—Nuclear extracts prepared from trans-
fected Raji cells were separated by SDS-PAGE and transferred
onto polyvinylidene difluoride membranes. The membranes
were then blocked in Tris-buffered saline containing 5% nonfat
dry milk and incubated with an anti-c-Myc (1/1000 dilution;
Santa Cruz Biotechnology, catalog number sc-40) antibody or
with an antibody from Imgenex directed against DNMT1
(IMG-261A),DNMT3A (IMG-268A), orDNMT3B (IMG-184A).
A second antibody, a horseradish peroxidase-conjugated goat
anti-rabbit IgG (1/3000 dilution; Santa Cruz Biotechnology,
sc-2054), was used for enhanced chemiluminescence detection
(Cell Signaling Technology).
Bisulfite Cytosine Methylation Analysis—Samples of total
genomic DNA (700 ng) isolated with the DNeasy tissue kit
(Qiagen) and digested overnight with EcoRI in a volume of 20
l were prepared for methylation analysis as described previ-
ously by Olek et al. (39). Briefly, the digested DNA, which had
been boiled for 5 min, chilled quickly on ice, and incubated in
0.3 MNaOH at 50 °C for 15min, was mixed with 2.5 volumes of
2% low melting point agarose (SeaPlaque agarose, FMC Bio-
products). Ten-microliter volumes of agarose-DNA mixture
were pipetted into 750 l of chilled mineral oil to form agarose
beads. Aliquots of 1 ml of 2.5 M sodium metabisulfite (Sigma)
and 125mMhydroquinone (Sigma) (pH 5.0) were then added to
mineral oil containing up to four agarose beads. The reaction
mixtures were kept on ice for 30 min and then incubated in the
dark at 50 °C for 3.5 h. The agarose beadswere equilibrated four
times (15 min each time) with 1 ml of Tris-EDTA (pH 8.0) and
DNA desulfonated in 500 l of 0.2 M NaOH (twice for 15 min
each time) at room temperature. Finally, the beadswerewashed
with 1ml of Tris-EDTA (pH 8.0) (3 times for 10min each time)
and then with 1 ml of sterile water (twice for 15 min each time)
and kept at 4 °C.
Bisulfite-treated DNA in melted agarose was amplified by
PCR in a 100-l reaction mixture containing 1 PCR buffer
(GoTaq polymerase buffer, Promega, Madison, WI), 1 mM
MgCl2, each dNTP at 400M,with 1 unit ofGoTaq polymerase,
and 50 pmol of each primer: NA (5-TGTATGAAAGAT-
TATGT-3, nucleotides (nt)211 to195, sense) and NB (5-
CATAATATAATTTAAAAAAAAAACCCAAAA-3, nt 391–
420, antisense), primers complementary to theBLV5-LTRand
Gag-coding region, respectively (Fig. 2C); NE (5-TAGAAAA-
TGAATGGTTTTTT-3, nt 7930–7949, sense) and NF (5-
TATTTACCAATCTCTCCTAA-3, nt 8484–8503, anti-
sense), primers complementary to theX region and the 3-LTR,
respectively (Fig. 2C). The amplification products were sub-
jected to a second round of PCR with nested primers: NC (5-
GATTATGTTGATTTAGGAGT-3, nt202 to183, sense)
and ND (5-AAAATAAATCCAAAAAATTATTAAAAT-
TCC-3, nt 351–380, antisense), primers complementary to the
BLV 5-LTR and Gag coding regions, respectively (Fig. 2C);
NG (5-GAGGGGGAGTTATTTGTATG-3, nt 8060–8079,
sense) and NH (5-TATTTACCAATCTCTCCTAACC-3, nt
8482–8503, antisense), primers complementary to BLV
3-LTR andX regions, respectively (Fig. 2C). The sense primers
containedT and the antisense primers containedA instead of C
in positions complementary to nonmethylable C (i.e. C out of
CpG dinucleotides). PCR was performed with about 50 ng of
genomic DNA (of 140 ng of DNA/1 agarose bead) for 40 cycles
at 95 °C for 1 min, 50 °C (45 °C for the 3-LTR) for 2 min, and
72 °C for 1 min 30 s for the first round of PCR. The second
round of PCR was performed with 5 l from the first round of
PCR for 50 cycles at 95 °C for 1 min, 56 °C for 2 min (52 °C for
the 3-LTR), and 72 °C for 1 min 30 s. Amplification products
were cloned in the TOPO TA cloning vector system (Invitro-
gen) and sequenced. The frequency of conversion of C to T
following the sodiumbisulfite treatment andPCR in our studies
was greater than 99% at non-CpG sites, indicating the adequacy
of the approach.
ChIP Assays—ChIP assays were performed using the ChIP
assay kit (EZ ChIP technology, Upstate). YR2 and L267 cells
were cross-linked for 10 min at room temperature with 1%
formaldehyde. To detect chromosomal flanking regions, pellets
were sonicated (Bioruptor sonicator) to obtain DNA fragments
at an average size of 400 bp. Chromatin immunoprecipitations
were performedwith an antibody directed against CREB (Santa
Cruz Biotechnology, catalog number sc-186), CREM (sc-440),
ATF-1 (sc-243), and ATF-2 (sc-242). To test aspecific binding
to the beads, a purified IgG was used as a control for immuno-
precipitation (Vector Laboratories, catalog number I-1000).
Quantitative PCR reactions were performed with the MESA
GREEN qPCR MasterMix (Eurogentec). Relative quantifica-
tion using standard curve method was performed for each
primer pair, and 96-well optical reaction plates were read in an
Applied Biosystems ABI Prism 7300 real-time PCR instrument
BLV Promoter Transcriptional Repression via CpGMethylation
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(absolute quantification method). Fold enrichments were cal-
culated as percentages of input values following this formula:
Immunoprecipitated DNA/total DNA. Primer sequences used
for quantification in a region overlapping the three CRE sites of
the BLV LTR (Fw, 5-GCCAGAAAAGCTGGTGACG-3 and
Rv, 5-GGGTGTGGATTTTTCGGG-3) and in the U5 region
of the BLV LTR, where no CRE binding site has been reported
(Fw, 5-CCTCTGACCGTCTCCACGT-3 and Rv, 5-AAGT-
AAGACAGGAAACAAGCGC-3), were designed using the
software Primer Express 2.0 (Applied Biosystems).
Electrophoretic Mobility Shift Assays—Nuclear extracts were
prepared from cells using a rapid protocol described byOsborn
et al. (40). All buffers contained the following protease inhibi-
tors: antipain (10 g/ml), aprotinin (2 g/ml), chymostatin (10
g/ml), leupeptin (1 g/ml), and pepstatin (1 g/ml). Protein
concentrations were determined according to the Bradford
methodology (41) with bovine serum albumin as a standard.
Electrophoretic mobility shift assays (EMSAs) were performed
as described previously (24). The DNA sequences of the coding
strand of TxRE1 and TxRE2 probes (nt 164 to 144 and nt
139 to 119, respectively) were as follows: 5-CAGACAG-
AGACGTCAGCTGCC-3 and 5-AGCTGGTGACGGCAG-
CTGGT-3 (theCRE sites are underlined, and theCpGdinucle-
otides are highlighted in boldface type). Methylated versions of
these oligonucleotides (where CpGs at positions154 (located
within the CRE1 site) or 129 (located within the CRE2 site)
were methylated) were synthesized chemically by Eurogentec
(Liege, Belgium) and named TxRE1-154me (Fw, 5-CAGACA-
GAGACMeGTCAGCTGCC-3; Rv, 5-GGCAGCTGACMeG-
TCTCTGTCTG-3) and TxRE2–129me (Fw, 5-AAGCTGG-
TGACMeGGCAGCTGGT-3; Rv, 5-ACCAGCTGCCMeG-
TCACCAGCTT-3).
Plasmid Constructs and Generation of Constructs with Site-
specific Methylation—The eukaryotic expression vector
pSG-TaxBLV was a kind gift from Drs. Richard Kettmann and
Luc Willems (Faculty of Agronomy, Gembloux, Belgium). The
eukaryotic pcDNA3.1/Myc-His-derived expression vectors for
DNMT1, DNMT3A, and DNMT3B (pCMV-Myc-Dnmt1,
pDNMT3aMyc, and pDNMT3bMyc, respectively) were kind
gifts fromDrs. Franc¸ois Fuks andTonyKouzarides (42, 43). The
non-episomal plasmid pLTRwt-luc and the episomally repli-
cating plasmid pLTR*wt(direct)-luc were described previously
(in Refs. 24 and 27, respectively) and contain the luciferase gene
under the control of the complete 5-LTR of the 344 BLV pro-
virus. Strain 344 is an infectious and pathogenic molecular
clone (33). The vector pLTRwt-luc was used as a substrate for
mutagenesis with the QuikChange site-directed mutagenesis
method (Stratagene) using 50 ng of pLTRwt-lucDNA/reaction.
Following PCR, the samples were treated with DpnI for 2 h to
remove the DNA template. The products were purified using
the QIAquick method (Qiagen), reannealed, and precipitated.
DNA concentration was determined by UV absorbance before
transfection. Mutations in the CRE1 and CRE2 sites were gen-
erated with the following pairs of mutagenic oligonucleotides:
CRE1 (Fw, 5-CAGACAGAGTGGTCAGCTGCC-3; Rv,
5-GGCAGCTGACCACTCTGTCTG-3) and CRE2 (Fw, 5-
AAGCTGGTGTGGGCAG CTGGT-3; Rv, 5-ACCAGC-
TGCCCACACC AGCTT-3) (mutations are highlighted in
boldface type, and theCREmotif is underlined). Thesemutated
plasmids were designated pLTRmutCRE1 and pLTRmutCRE2,
respectively. All mutated constructs were fully sequenced after
identification (Genome Express).
The pLTRwt-luc vector with methylation either at the154
CpG, or the129 CpG or at both CpGs in combination (154
CpG and129 CpG) was generated using site-specific methy-
lated oligonucleotides (purchased from Eurogentec) and the
QuikChange site-directed mutagenesis kit (Stratagene) follow-
ing a protocol adapted from Martinowich et al. (44). In brief,
two oligonucleotide primers, each complementary to opposite
strands of the parental vector andmethylated at the154 CpG
(Fw, 5-CAGACAGAGACMeGTCAGCTGCC-3; Rv, 5-GGC-
AGCTGACMeGTCTCTGTCTG-3) or the129 CpG (Fw, 5-
AAGCTGGTGACMeGGCAGCTGGT-3; Rv, 5-ACCAGCT-
GCCMeGTCACCAGCTT-3), were extended by the PfuTurbo
DNApolymerase. The product of this reactionwas then treated
with the endonuclease DpnI, which is specific for methylated
and hemimethylated DNA (target sequence 5-Gm6ATC-3),
and digested the parental DNA template to select formutation-
containing synthesized DNA. This experimental strategy led to
the production of circular closed plasmids with site-directed
methylation on both strands. These CpG methylated plasmids
were designated pLTR-154me, pLTR-129me, and pLTR-
154me/-129me, respectively, and transfected directly after
the mutagenesis reaction without amplification in bacteria.
As an additional control, we generated pLTRwt-luc and
pLTR*wt(direct)-luc derivatives, which were hypermethylated
only in the LTR (i.e. in which every CpGof the BLVLTR, but no
CpGelsewhere in the pLTRwt-luc or pLTR*wt(direct)-luc plas-
mid,weremethylated in vitroby the SssImethyltransferase). To
this end, we methylated in vitro the whole pLTRwt-luc (or
pLTR*wt(direct)-luc) plasmid with SssI and then cloned back
the purified fragment corresponding to the LTR in the parental
reporter vector pGL3basic (or pREP10), thereby generating
pLTRmSssIme (or pLTR*mSssIme).
RNA Purification and Analyses of Transcripts—Total RNA
samples were extracted from 1  106 cells using the RNeasy
Plusmini kit (Qiagen) according to themanufacturer’s instruc-
tions and digested with TURBO DNase I (TURBO DNA-
freeTM kit, Ambion) to ensure the removal of genomic DNA.
First strand cDNA was synthesized using SuperScript III
reverse transcriptase (Invitrogen). Quantitative real-time PCR
(qPCR) reactions were performed using MESA GREEN qPCR
MasterMix (Eurogentec), and 96-well optical reaction plates
were read in an Applied Biosystems StepOnePlus real-time
PCR system (comparative Ct (Ct) quantification method).
The following sets of primers were used for amplification of the
BLV 5-LTR and the -actin genes, respectively: Fw, 5-GAG-
ACCCTCGTGCTCAGCT-3, and Rv 5-CAGAAGGTCTCG-
GGAGCAA-3; and Fw 5-TCCACTGCTCCTGTCTTCGA-
3, and Rv 5-GATCTTTTCCCGTCCCAAAGT-3. Primer
sequences used to quantify DNMT1, DNMT3A, andDNMT3B
mRNAswere as follows: DNMT1 (Fw, 5-ACGCTAACGAAT-
CTGGCTTTG-3; Rv, 5-CGCGTTTACAGTACACGCTG-
3); DNMT3A (Fw, 5-CTGGGTCATGTGGTTCGG-3; Rv,
5-GCACTGCAAAACGAGCTCAG-3); and DNMT3B (Fw,
BLV Promoter Transcriptional Repression via CpGMethylation
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5-TTTGGCGATGGCAAGT TCT-3; Rv, 5-GGCCAAATT-
AAAGTGCTGGC-3).
ELISA—After culture, the cells were harvested by centrifuga-
tion, and the supernatants were removed. The BLV p24 protein
in the supernatants was titrated by an immunoenzymatic cap-
ture technique as described by Portetelle et al. (45).
RESULTS
Activation of BLV Promoter Transcriptional Activity by
Inhibitors of DNAMethylation—Our laboratory had previously
demonstrated that histone acetylation is an important chroma-
tinmodification for TaxBLV-dependent and -independent tran-
scriptional regulation of BLV (26–28). To further study the
molecular mechanisms underlying the epigenetic control of
BLV expression, we examined the potential role of DNAmeth-
ylation in BLV transcriptional activity. To this end, we tested
the effects of DNA methylation inhibitors on transcriptional
activity of the BLVpromoter (the 5-LTR) in transient transfec-
tion experiments (Fig. 1). A pLTRmSssIme reporter plasmid
containing the firefly luciferase (luc) gene under the control of
the complete BLV 5-LTR (nucleotides 211 to 320) (24),
which had been methylated previously in vitro by the Sss1
methyltransferase (see “Experimental Procedures”), was tran-
siently transfected into the human B-lymphoid Raji cell line.
Transfected cells were mock-treated or treated with increasing
concentrations of procaine (0–10 mM), procainamide (0–10
mM), 5-aza-2-deoxycytidine (5-AZAdc) (0–200 nM), or zebu-
larine (0–1 mM) for 72 h and assayed for luciferase activity. As
shown in Fig. 1A, the BLV LTR was activated in a dose-depen-
dent manner by each of the four DNA methylation inhibitors
used. pLTRmSssIme presented procaine inductions varying
from 1.3- to 4.9-fold, procainamide inductions varying from
1.3- to 3.2-fold, 5-AZAdc inductions varying from 1.6- to 2.9-
fold, and zebularine inductions varying from 1.0- to 9.3-fold.
Similar results were observed using the human B-lymphoid
DG75 cell line (data not shown). Bisulfite sequencing analyses
revealed that the increased transcriptional activity of the BLV
LTR following treatment of the cells with each of the four DNA
methylation inhibitors used was correlated with a partial CpG
demethylation in the U3 and R regions of the BLV LTR (data
not shown).
Because transiently transfected DNA does not always form
proper chromatin structure, we next wanted to confirm the
above described transient transfection results in a nucleosomal
context. To this end, we used an episomally replicating BLV
LTR-luc reporter plasmid (pLTR*wt(direct)-luc), described
previously by our laboratory from amodified pREP10 episomal
vector that contained the Epstein-Barr virus replication origin
and encoded nuclear antigen EBNA-1 (27). Several studies have
reported that pREP-based episomal constructs display the hall-
marks of proper chromatin structure when transiently trans-
fected into cells (46–49). We transiently transfected into Raji
cells the episomally replicating pLTR*mSssIme plasmid, where
the BLV promoter had been methylated previously in vitro by
the Sss1 methyltransferase. Transfected cells were mock-
treated or treated with increasing concentrations of the four
precited DNAmethylation inhibitors and assayed for luciferase
activity. As shown in Fig. 1B, the BLVpromoterwas activated in
a dose-dependentmanner by procaine (up to 4.0-fold), procain-
amide (up to 3.4-fold), 5-AZAdc (up to 4.5-fold), and zebularine
(up to 4.7-fold). Moreover, a cellular model in which a BLV
5-LTR-luciferase cassette was stably integrated into the
B-lymphoid DG75 cell line (construction named clone 27; its
characterization is part of a separate, unpublished study from
our laboratory) was also used to address the effect of DNA
FIGURE 1. Activation of BLV LTR activity by DNA methylation inhibitors.
A, Raji cells were transiently transfected using the DEAE-dextran procedure
with 500 ng of pLTRmSssIme, where the BLV LTR had previously been meth-
ylated in vitro by the SssI methyltransferase. At 22 h after transfection, cells
were mock-treated or treated with increasing concentrations of procaine (0,
2.5, 5, 7.5, and 10mM), procainamide (0, 2.5, 5, 7.5, and 10mM), 5-AZAdc (0, 50,
100, 150, and 200 nM), or zebularine (0, 0.05, 0.1, 0.25, and 0.5 mM). Luciferase
activitiesweremeasured in cell lysates 96 h after transfection andnormalized
to protein concentrations. Results are presented as histograms indicating
the procaine, procainamide, 5-AZAdc, and zebularine inductions of
pLTRmSssImewith respect to its basal activity, which was assigned a value of
1. Means S.E. are shown. Results from a representative experiment of three
independent transfections are shown. B, Raji cells were transiently trans-
fected using theDEAE-dextran procedurewith 500 ng of the episomal vector
pLTR*mSssIme,where theBLVLRThadpreviouslybeenmethylated in vitroby
the SssI methyltransferase. At 22 h posttransfection, cells were mock-treated
or treated with increasing concentrations of procaine (0, 0.1, 0.5, 1, and 10
mM), procainamide (0, 0.1, 0.5, 1, and 10mM), 5-AZAdc (0, 250, 500, 1000, and
2500 nM), or zebularine (0, 0.05, 0.075, 0.1, and 1 mM). Luciferase activities
were measured in cell lysates 96 h after transfection and normalized to pro-
tein concentrations. Results are presented as histograms indicating the pro-
caine, procainamide, 5-AZAdc and zebularine inductions of pLTR*mSssIme
with respect to its basal activity,whichwas assigned a valueof 1.Means S.E.
are shown. The results from a representative experiment of three indepen-
dent transfections are shown.
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methylation inhibition. Using clone 27, we observed that
increasing concentrations of DNA methylation inhibitors
enhanced BLV5-LTR-directed luciferase expression in a dose-
dependent manner (data not shown). These results demon-
strate that the BLV LTR-directed gene reporter expression is
activated in a dose-dependent manner in response to selective
DNA methylation inhibitors in the context of non-episomal
and episomal LTRmethylated constructs, thereby suggesting a
role of DNA methylation in BLV transcriptional regulation.
Hypermethylation of the U3 and R Regions in the BLV 5-LTR
in L267 Lymphoma-derived B-cell Line—To further examine
the potential role of DNAmethylation in transformation-asso-
ciated BLV silencing, we investigated theDNAmethylation sta-
tus of the 5-LTR in the context of integrated BLV proviruses.
To this end, we used three different BLV-infected cell lines
representing two distinct viral transcriptional states: the YR2
and L267 cell lines, which represent the silent/nonproductive
state, and the L267LTaxSN cell line, which represents the pro-
ductive state. On the one hand, the YR2 cell line is an ovine
B-cell line, which was cloned from leukemic B cells of a BLV-
infected sheep (10, 36, 37, 50). This cell line contains a single
monoclonally integrated silent provirus in which two Glu-to-
Lys amino acid substitutions in the TaxBLV protein impair the
infectious potential of the integrated provirus (33). The L267
cell line is a B-cell line isolated from sheep S267, a BLV-infected
sheep injected with naked proviral DNA of an infectious BLV
variant (33–35). Provirus expression is completely suppressed
in L267 lymphoma B cells, as demonstrated conclusively by
their incapacity to generate infection in the in vivo sheepmodel,
and the tumor-derived L267 provirus displays a wild-type
sequence that is identical to the infectious provirus used for
sheep S267 inoculation (34, 35). In contrast to the YR2 cell line,
which represents a defective latency state, the L267 cell line
represents a true latency state, i.e. a reversible transcriptionally
silent but replication-competent provirus. On the other hand,
the L267LTaxSN cell line is a virus-expressing cell line resulting
from transduction of the native L267 cell line with a retroviral
vector pLTaxSN expressing a wild-type TaxBLV protein. Trans-
duction of this TaxBLV coding vector restores viral expression
from the silent integrated provirus (34).
To verify the productive versus nonproductive state of our
cell lines, we first measured BLV transcripts by reverse tran-
scription qPCR in each of the three cell lines.We observed very
low levels of viral transcripts in the YR2 and L267 cell lines, as
compared with the L267LTaxSN cell line, which abundantly pro-
duces BLV mRNAs (Fig. 2A). Similarly, measurement of p24
major capsid antigen by ELISA in the supernatants of all cul-
tured cell lines showed a dramatic increase in the production of
this structural antigen in the L267LTaxSN cell line compared
with the silent L267 and YR2 cell lines (Fig. 2B). These results
indicate that exogenous TaxBLV is capable of restoring viral
expression from silent integrated proviruses, in agreementwith
previous studies (34).
To determine the methylation status of each CpG dinucle-
otide in the 5-LTR of integrated BLV proviruses, we used the
sodium bisulfite sequencing technique to analyze genomic
DNA from the YR2, L267, and L267LTaxSN cell lines. To distin-
guish between the 5- and 3-LTRs, which have the same nucle-
otide sequence, we used reverse primers located in the gag gene
(Fig. 2C, primers NB andND) or forward primers located in the
X region (primersNE andNG) for the nested PCR, respectively.
As shown in Fig. 2C, the U3 region and the 5-half of the R
region of the 5-LTR in L267 cells were densely methylated.
Indeed, six consecutive CpGdinucleotides in theU3 region and
nine consecutive CpG dinucleotides in the R region, overlap-
ping the transcription initiation site, were strongly methylated.
Among these methylated CpGs, the 154 CpG and the 129
CpG (located in the distal CRE1 andmiddle CRE2 sites, respec-
tively) were methylated in 100% of the cloned sequences tested
for the L267 cell line. These two methylated 154 and 129
CpGs are indicated by asterisks in Fig. 2C. In the L267LTaxSN
cells, only the 5-half of the R region was methylated although
to a lesser extent than in the L267 cells. Remarkably, the 5-LTR
in the YR2 cell line was completely unmethylated.
In all retroviruses, LTRs localized at the 5 and 3 extremities
of the proviral genome have identical nucleotide sequences but
display different functions; the 5-LTR functions as a transcrip-
tional promoter, whereas the 3-LTR has a polyadenylation
function. Therefore, we addressed the question of differential
CpG methylation patterns in the sequentially identical but
functionally different BLVLTRs.Our bisulfite sequencing anal-
ysis of the 3-LTR revealed a lack of CpG methylation in the
three tested cell lines: YR2, L267, and L267LTaxSN (Fig. 2C).
In conclusion, our results indicate that the BLV true latency
state correlates with CpG hypermethylation in the 5-LTR U3
and R regions of the integrated proviral DNA, directly demon-
strating for the first time the association of this epigeneticmod-
ification with a specific viral expression state. This could be a
viral strategy to escape host immune response and allow tumor
onset and propagation. Importantly, these methylation marks
were not observed in the YR2 proviral system, representative of
a defective latency state.
Ectopically Expressed DNMT1 and DNMT3A, but Not
DNMT3B, Down-regulate BLV Promoter Activity—To address
the role of DNMTs in transcriptional regulation of the BLV
promoter, transient cotransfections of Raji cells were per-
formed with the pLTRwt-luc reporter construct and increasing
amounts of expression vectors coding for DNMT1, DNMT3A,
or DNMT3B. As shown in Fig. 3A and B, DNMT1 and
DNMT3A strongly repressed basal LTR-directed gene expres-
sion, suggesting that these DNMTs could negatively regulate
BLV promoter activity. In contrast, DNMT3B had no effect on
reporter gene expression (Fig. 3C), suggesting a certain func-
tional specificity of DNMTs in the transcriptional regulation of
the BLV promoter. Western blot experiments allowed us to
verify the efficiency of each DNMT overexpression in correla-
tion with the level of BLV 5-LTR promoter activity (Fig. 3).
These results confirmed that the inability of DNMT3B to
repress BLV 5-LTR activity was not due to a lack of DNMT3B
protein expression (Fig. 3C).
In addition, we performed ChIP experiments to evaluate in
vivo the recruitment of DNMTs to the BLV promoter using
chromatin samples prepared from the transiently transfected
cells. We immunoprecipitated the chromatin either with an
antibody directed against the c-Myc epitope fused to the differ-
ent DNMTs present in the recombinant expression vectors we
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had used in the overexpression experiments or with antibodies
directly targeting DNMT1, DNMT3A, or DNMT3B. However,
we did not succeed in detecting any statistically relevant ChIP
signal compared with the negative control (consisting of a puri-
fied IgG antibody). In additional ChIP experiments, we used
chromatin samples from YR2 and L267 cells to study DNMT
recruitment in vivo to the hypomethylated and hypermethyl-
ated BLV promoters, respectively. Despite many attempts, we
could not detect in vivo the re-
cruitment of these DNMTs to the
BLV 5-LTR region in our ChIP
assays neither with the chromatin
extracted from the transiently
transfected cells nor with the chro-
matin prepared from the BLV-in-
fected cell lines YR2 and L267 (data
not shown).
Moreover, we evaluated the DNA
methylation profile of the BLV LTR
in the LTR-reporter constructs
following overexpression of each
DNMT. Methylation-sensitive re-
striction analyses revealed that
overexpression of DNMT1 and
DNMT3A (and to a lesser extent
DNMT3B) increased CpGmethyla-
tion in the BLV LTR. However, the
results we obtained by the bisulfite
sequencing technique revealed in
each case a very weakly methylated
profile (data not shown), which did
not correspond to the methylation
pattern we observed in the infected
cell lines (see Fig. 2C), thereby sug-
gesting that the establishment of the
DNA methylation profile during
or after natural integration into
the host cell genome can not be
recapitulated using LTR-reporter
constructs.
Taken together, our results sug-
gest that the activity of the BLV
promoter is negatively regulated
by the DNA methyltransferases
DNMT1 and DNMT3A but not by
DNMT3B. However, we could not
demonstrate the recruitment of
these enzymes in vivo in the BLV
5-LTR region.
Synergistic Activation of BLV Pro-
moter by TaxBLV and DNA Methy-
lation Inhibitors—To examine the
potential link between DNA meth-
ylation and TaxBLV transactivation,
we tested the effect of two DNA
methylation inhibitors (5-AZAdc
and procaine) on basal and TaxBLV-
induced BLV LTR activity. To this
end, human B-lymphoid Raji cells were transiently cotrans-
fected with the pLTR-luc reporter construct (methylated in
vitro by Sss1 before transfection) and with increasing amounts
of a TaxBLV expression vector, pSG-TaxBLV. Twenty-two hours
posttransfection, transfected cells were mock-treated or
treated with either 5-AZAdc (250 M) or procaine (7.5 mM) for
72 h and assayed for luciferase activity (Table 1). As expected, in
the absence of 5-AZAdc or procaine, TaxBLV transactivated the
FIGURE 2. CpGmethylation status in the 5 and 3-LTR regions of BLV proviruses integrated in different
infectedcell lines.A,mRNAexpression levels in theBLV-infectedYR2, L267, andL267LTaxSN cell lines. Total RNA
samples were extracted and digested by DNase I. First strand cDNA was synthesized by reverse transcription,
and quantitative PCR was performed with oligonucleotide primers amplifying the 5-UTR region of BLV or the
-actin gene. Results are presented as the ratio of 5-UTR to -actin and are the mean values of triplicate
samples. The results froma representative experiment of three independent experiments are shown. B, ex vivo
expression of BLV in infected YR2, L267, and L267LTaxSN cell lines. The BLV p24 major gag antigen levels were
titrated in the culture supernatants by ELISA. Data are themean values of triplicate samples. The results from a
representative experiment of three independent ELISA experiments are shown. C, bisulfite sequencing analy-
sis of theCpGmethylation status in the 5- and3-LTRs of theYR2, L267, and L267LTaxSN cell lines. GenomicDNA
from the three cell lines was extracted and treated by sodium bisulfite/hydroquinone. The two LTRs were
amplified by nested PCR, amplified PCR products were subcloned in a TA cloning vector, and 10–11 clones
were sequenced for each cell line. The methylation status of these clones is presented for each cell line. The
positions and orientations of PCR primers (NA,NB,NC,ND,NE,NF,NG, andNH) used to amplify bisulfite-treated
BLV DNA by nested PCR are indicated by arrows.Open circles represent unmethylated CpG dinucleotides, and
filled circles represent methylated CpG dinucleotides. The154 CpG and129 CpG (located within the CRE1
and CRE2 sites, respectively) are hypermethylated in the L267 cell line and are indicated by asterisks.
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BLV promoter in a dose-dependent manner up to 985-fold
(Table 1, TaxBLV fold activation, lines 2–6). Treatment of trans-
fected cells with 5-AZAdc or procaine alone resulted in a 2.77-
or 5.31-fold activation of luciferase expression, respectively
(Table 1, line 1). Remarkably, when cells were both cotrans-
fectedwith increasing amounts of theTaxBLV expression vector
and treated with 5-AZAdc (or procaine), a strong synergism
was observed between TaxBLV and these DNA methylation
inhibitors, resulting in transactivations ranging from 134- to
2094-fold in the presence of 5-AZAdc (Table 1, lines 2–6,
TaxBLV  5-AZAdc fold activation) and from 350- to 3824-
fold in the presence of procaine (Table 1, lines 2–6,
TaxBLV  procaine fold activation). Transcriptional activators
synergize when their combination produces a transcriptional
rate that is greater than the sum of the effects produced by
individual activators (51). Transfection of 1 ng of pSG-TaxBLV
led to a 52.8-fold stimulation of transcription in the absence of
DNA methylation inhibitors, whereas in the presence of
5-AZAdc or procaine, it led to a 134- or 350-fold stimulation,
respectively (Table 1, line 2). This amount of transcription is
2.40- or 6.02-fold greater than the sumof the effect produced by
each activator separately (2.77 52.8 or 5.31 52.8) (Table 1,
line 2). Likewise, transfection of 8 ng of pSG-TaxBLV in the
presence of 5-AZAdc (or procaine) stimulated transcription
601 (or 1241)-fold, corresponding to a 2.82 (or 5.74)-fold syn-
ergism (Table 1, line 5). The data shown in Table 1 are pre-
sented in Fig. 4 as histograms indicating the synergistic activa-
tion (-fold) by TaxBLV and 5-AZAdc and by TaxBLV and
procaine (Fig. 4,A andB, respectively). This synergism between
TaxBLV and 5-AZAdc (or procaine) persisted even at saturating
amounts of the TaxBLV transactivator (data not shown), indi-
cating that the observed effect was not the consequence of
increased TaxBLV expression because of activation of simian
virus 40 (SV40) promoter by 5-AZAdc or procaine. Moreover,
we confirmed by Western blot experiments that 5-AZAdc or
procaine did not increase the amount of TaxBLV protein by
activating the SV40 promoter (data not shown). Similar results
were observed using another B-lymphoid cell line (the DG75
cell line; data not shown).
Synergistic activation by ectopically expressed TaxBLV and
inhibitors of DNA methylation required intact CRE binding
sites in the three BLV TxREs, because point mutations in
these three CRE motifs abrogated the synergistic effect
(pLTR-mut3CRE-luc; Table 1, lines 7–12, and Fig. 4). This
implied that the synergistic effect was mediated by interac-
tions at the CRE motifs and not at the otherwise intact LTR
BLV DNA sequences. In conclusion, these results demon-
strate that the DNA methylation inhibitors 5-AZAdc and
procaine synergistically enhance the transcriptional activity
of the BLV promoter mediated by TaxBLV in a CRE-depen-
dent manner.
Methylation at 154 CpG and 129 CpG in BLV 5-LTR
CRE1 and CRE2 Sites, Respectively, Impairs CREB, CREM, and
ATF-1 Binding—Our bisulfite sequencing results indicate that
the central CpGs located in the 5-LTR CRE1 and CRE2 sites
(i.e. 154 CpG and 129 CpG) are hypermethylated in the
integrated BLV provirus of L267 cells (Figs. 2C and 5). This
hypermethylation correlates with the transcriptionally silent
viral state in these cells. We investigated the in vitro effect of
methylation at the 154 CpG (distal CRE1 site) and at the
129 CpG (middle CRE2 site) on transcription factor binding
FIGURE 3. Response of the BLV promoter to ectopically expressed DNA
methyltransferases. Raji cells were transiently cotransfected using the
DEAE-dextran procedure with 500 ng of pLTRwt-luc and increasing amounts
(0, 50, 100, 250, 500, and 1000 ng of plasmid DNA) of the DNMT1, DNMT3A,
and DNMT3B expression vectors (A, B, and C, respectively). To maintain the
sameamountof transfectedDNAandavoid squelching artifacts, thedifferent
amounts of DNMT expression vector cotransfected were complemented to
1000 ng of DNA by using the empty vector. Luciferase activities measured in
cell lysates 44 h after transfectionwere normalized to protein concentrations.
The results are presented as histograms indicating the induction by DNMT1,
DNMT3A, or DNMT3B with respect to the activity of the reporter construct in
the absence of DNMT, which was assigned a value of 1. Means  S.E. are
indicated. A representative experiment of four independent transfections is
shown. Nuclear extractswere prepared and analyzedbyWestern blotwith an
anti-c-Myc antibody to detect DNMT1, DNMT3A, and DNMT3B expression
levels. These results are presented in parallel with the transfection results for
each DNMT.
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by EMSAs. For these studies, we used oligonucleotide probes
corresponding to the TxRE1 (nucleotides164 to144) or to
theTxRE2 (nucleotides139 to119) sites of theBLV5-LTR,
which were either unmethylated (referred to as TxRE1 or
TxRE2) ormethylated at the154 or129 CpG (referred to as
TxRE1–154me or TxRE2–129me, respectively). These probes
were incubated with nuclear extracts from the latently BLV-
infected B-cell line L267 treated (Fig. 6, A and B, lanes 2 and 7)
or not (lanes 1 and 6) with a combination of PMA ionomycin
(PI), two known activators of BLV expression (26, 52, 53);
from the defective cell line YR2 treated (lanes 4 and 9) or not
(lanes 3 and 8) with PMA ionomycin; or from PBMCs
derived from a BLV-infected sheep (BLV-infected sheep M298
presenting a persistent lymphocytosis) (lanes 5 and 10). When
the EMSAs were carried out with the unmethylated oligonu-
cleotide TxRE1 and TxRE2 probes, we observed, as reported
previously by our laboratory (17), a minor and two major
retarded bands (called C1, C2, and C3, respectively) (Fig. 6, A
and B, lanes 1–5). Our laboratory had previously reported that
the C1 complex contains the ATF-2 transcription factor and
the C2 complex contains ATF-1, CREB, and CREM proteins
(14, 15, 17, 27). Supershift experiments did not identify the
nature of the proteins present in complexC3 (17). Treatment of
YR2 or L267 cells with PMA ionomycin increased the inten-
sity of the retardedDNA-protein complexC2 as comparedwith
mock-treated cells (Fig. 6, A and B, compare lanes 1 and 2 and
lanes 3 and 4). Moreover, we observed a strong binding of
CREB/CREM/ATF-1 proteins to the TxRE1 and TxRE2 probes
when these probes were incubated with nuclear extracts pre-
pared from BLV-infected PBMCs (Fig. 6, A and B, lanes 5).
Remarkably, when the methylated TxRE1–154me probe or the
methylated TxRE2–129me probe was used, we observed the
complete disappearance of complex C2, even with nuclear
extracts from infected PBMCs or from PMA ionomycin-
treated YR2 or L267 cells (Fig. 6, A and B, compare lanes 1–5
with lanes 6–10). Following PMA ionomycin treatment of
YR2 cells, complex C1 seemed to migrate slower than in
mock-treated cells (Fig. 6A, compare lanes 3 and 4), but we
could not identify by supershift experiments any potential
additional (co)factor(s) associated with complex C1 follow-
ing PMA  ionomycin treatment (data not shown). How-
ever, complex C1 was not observed when PBMC nuclear
TABLE 1
Synergistic activation of BLV promoter activity by TaxBLV and inhibitors of DNAmethylation
Raji cells were transiently cotransfected using the DEAE-dextran procedure with 500 ng of either the pLTRwt-luc (lines 1–6) or pLTR-mut3CRE-luc (lines 7–12) (both
methylated in vitro by the SssImethyltransferase before transfection) andwith increasing amounts of pSG-TaxBLV (from0 to 100 ng of plasmidDNA). Tomaintain the same
amount of transfected DNA and to avoid squelching artifacts, the different amounts of pSG-TaxBLV cotransfected were complemented to 100 ng of DNAby using the pSG5
empty vector. Twenty-two hours posttransfection, cells weremock-treated or treatedwith either 5-AZAdc (250M) or procaine (7.5mM) for 72 h. Luciferase activities were
measured in cell lysates 96 h after transfection and normalized with respect to protein concentrations. Results are presented as relative light units (RLU), TaxBLV fold
activation, TaxBLV 5-AZAdc fold activation, and TaxBLV procaine fold activation of the reporter constructs (pLTRwt-luc and pLTR-mut3CRE-luc) with regard to their
respective basal activity level, whichwas arbitrarily set at a value of 1. TheTaxBLV 5-AZAdc (orTaxBLV procaine) fold synergismwas determined as described previously
(51) using the following formula: [Fold activation by TaxBLV  5-AZAdc (or TaxBLV  procaine)]/{[fold activation by TaxBLV alone]  [fold activation by 5-AZAdc (or
procaine) alone]}. Values represent the means of triplicate samples with S.E. indicated in parentheses. An experiment representative of four independent transfections is
shown.
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extracts were used (Fig. 6, A and B, lanes 5), suggesting a
minor function of this complex.
To confirm these results, unlabeled double-stranded oligo-
nucleotides were prepared and used as competitors in the
EMSAs with the unmethylated TxRE1 or TxRE2 probe and
nuclear extracts from BLV-infected PBMCs (supplemental Fig.
S1,A or B, respectively). As shown previously by our laboratory
(17), formation of complex C2 was competed out by molar
excesses of the TxRE1 or TxRE2 unlabeled homologous oligo-
nucleotides but not by the same molar excesses of a heterolo-
gous oligonucleotide of unrelated sequence. Moreover, the C2
complex was not or was weakly competed out by the same
molar excesses of methylated TxRE1–154me (supplemental
Fig. S1B) or TxRE2–129me (supplemental Fig. S1A) unlabeled
oligonucleotides, respectively, thereby confirming that forma-
tion of complex C2 was dependent on the presence of an
unmethylated TxRE1 or TxRE2 sequence (supplemental
Fig. S1). Altogether, these results indicate that methylation at
the 154 CpG or at the 129 CpG abolish in vitro binding of
the CREB/CREM/ATF-1 transcription factors to the CRE1 or
CRE2 site, respectively.
To confirm these results in vivo, we conducted ChIP experi-
ments using the YR2 and L267 cell lines, representative of
defective and true latency, respectively. These two cell lines
allowed us to compare CREB/CREM/ATF recruitment to the
hypomethylated YR2 BLV 5-LTRwith their recruitment to the
hypermethylated L267 BLV 5-LTR.We used specific antibod-
ies directed against CREB, CREM, ATF-1, and ATF-2 proteins
and a purified IgG antibody as a control. Two different probes
were designed in the BLV 5-LTR to compare the recruitment
of these proteins to the TxRE site region with their recruitment
to the U5 region in which no CRE sites had been reported pre-
viously. As shown in Fig. 6C, we observed the recruitment of
transcription factors CREB and CREM, and to a lesser extent
ATF-1, to the hypomethylated CRE region of YR2 5-LTR. In
contrast, no CREB/CREM/ATF recruitment was observed to
the hypermethylated corresponding region in the L267 cell line
(Fig. 6C).Moreover, in both cell lines, theATF-2 protein, which
is part of complex C1 (see the EMSAs in Fig. 6, A and B, and as
reported previously by our laboratory (17)), did not seem to be
recruited in vivo to the 5-LTR region (Fig. 6C). This latter
result is in agreement with our in vitro binding studies showing
that complex C1, which contains the ATF-2 transcription fac-
tor, is not the major retarded band observed in gel shift assays
using theTxREprobes (Fig. 6,A andB), suggesting a less impor-
tant function of ATF-2 compared with that of CREB/CREM/
ATF-1. Altogether, these results indicate that CpGmethylation
impairs in vivo CREB/CREM/ATF-1 binding to the CRE bind-
ing sites of the BLV 5-LTR.
Methylation at the 129 CpG in the CRE2 Site Down-regu-
lates BLV 5-LTR Transcriptional Activity—To assess the tran-
scriptional regulatory function of methylation at the154 and
129 CpGs, we modified the pLTRwt-luc vector so that the
154 CpG and/or the 129 CpG were methylated by a PCR-
mediated mutagenesis protocol (see “Experimental Proce-
dures” and Ref. 44). As controls, we also generated, by the same
technique, an unmethylated pLTRwt-luc as well as unmethyl-
ated mutant reporter constructs named pLTRmutCRE1 or
pLTRmutCRE2, which contained point mutations abolishing
CREB/CREM/ATF-1 transcription factor binding to the CRE1
or CRE2 site, respectively. Directly after purification, the PCR
products from these site-directed mutagenesis experiments
were transiently transfected into the human epithelialHeLa cell
line (which presents high transfection efficiency). At 44 h post-
transfection, cells were lysed and assayed for luciferase activity.
As shown in Fig. 7A, methylation at the 129 CpG caused a
46% decrease in luciferase activity. Methylation at the 154
CpG did not affect basal BLV LTR-directed gene expression.
Moreover, when combined withmethylation at the129 CpG,
methylation at the 154 CpG did not further decrease BLV
promoter activity compared with what we observed with the
plasmid methylated only at the129 CpG.
Point mutation in the CRE1 site (pLTRmutCRE1) or in the
CRE2 site (pLTRmutCRE2) caused a 35 or 71% decrease,
respectively, of basal LTR-directed gene expression.As an addi-
tional control, we generated a pLTRwt-luc derivative that was
hypermethylated only in the LTR (i.e. inwhich everyCpGof the
5-LTR, but no CpG elsewhere in the pLTRwt-luc plasmid, was
methylated in vitro by SssI methyltransferase). This construc-
tion was named pLTRmSssIme (see “Experimental Proce-
dures”). As shown in Fig. 7A, when transiently transfected the
FIGURE 4. -Fold activation of the BLV promoter activity by TaxBLV and
inhibitors of DNMTs. The histograms represent -fold inductions of BLV pro-
moter activity by TaxBLV and 5-AZAdc (A) or procaine (B) as detailed in Table 1.
Values represent the means of triplicate samples  S.E. are indicated. An
experiment representative of four independent transfections is shown.
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pLTRmSssIme exhibited a 72% decrease in luciferase activity
compared with that observed with the unmethylated pLTRwt-
luc construct.
To validate our method, we performed additional inde-
pendent transfection experiments using the pLTRwt-luc,
pLTRmutCRE1, and pLTRmutCRE2 constructs resulting from
the samePCRmutagenesis technique but followedby a classical
amplification step in bacteria and not directly transfected after
purification of the mutagenized PCR products. These con-
structs were transiently transfected into HeLa cells. At 44 h
posttransfection, cells were lysed and assayed for luciferase
activity. As shown in Fig. 7B, mutation in the CRE1 or the CRE2
site reduced BLV promoter activity by 39 or 75%, respectively.
Remarkably, these reductions were almost identical to those
observed by directly transfecting the same plasmids after
mutagenesis (compare pLTRmutCRE1 and pLTRmutCRE2 in
Fig. 7), thereby validating themutagenesis techniquewe used in
Fig. 7A.
Altogether, these results demonstrate thatmethylation at the
129CpG significantly reduces BLVpromoter-driven reporter
gene expression, whereas methylation at the154 CpG has no
effect on the BLV promoter activity. These data suggest that
methylation at the 154 CpG position in the BLV promoter,
even if it impairs CREB/CREM/ATF-1 transcription factor
binding, does not interfere with basal transcriptional activity of
this promoter ex vivo.
Transactivator Protein TaxBLV Down-regulates DNMT
Expression—In our bisulfite sequencing experiments, we
observed a partial loss of DNAmethylation of the BLV 5-LTR
in L267LTaxSN cells compared with L267 cells (Fig. 2C). A pos-
sible explanation is that the transactivating TaxBLV protein
could decrease the expression level of DNA methyltrans-
ferases. In order to address this issue, we quantified DNMT1,
DNMT3A, and DNMT3B protein expression levels in the
L267LTaxSN cell line compared with the L267 cell line by
Western blot experiments. Remarkably, DNMT1 and
DNMT3B protein expression was strongly down-regulated
in L267LTaxSN cells compared with L267 cells (Fig. 8A). How-
ever, we could not assess the protein level of DNMT3A
because no ovine antibody against DNMT3A was available
commercially and the murine anti-DNMT3A antibody did
not reveal any specific band in either L267 or L267LTaxSN
cellular extracts. We next measured DNMT mRNA expres-
sion levels in these two cell lines by reverse transcription
FIGURE 5. Schematic representation of the BLV 5-LTR alignedwith the CpGmethylation pattern of the L267 cell line. The transcription initiation site at
the U3–R junction of the 5-LTR (mRNA start site is at1 nt) is indicated by an arrow. The TxREs are three major transcriptional enhancer sequences of 21 bp,
which interact with the cellular transcription factors CREB, CREM, ATF-1, and ATF-2 and which are required for the transcriptional activation of the BLV LTR by
the virus-encoded TaxBLV transactivator. Each of the 21-bp enhancers contains a sequence homologous to the consensus E-box bindingmotif (E-box1, E-box2,
and E-box3) overlapping an imperfect CRE (CRE1,CRE2, andCRE3). TheU3 region also contains a glucocorticoid-responsive element (GRE) and a PU.1/Spi-B site.
AUSF-1/USF-2binding site (E-box4) andan interferon regulatory factor (IRF-1/IRF-2)-binding site are located in theR regionand theU5 region, respectively. The
results of bisulfite genomic sequencing that we obtained in the L267 cell line are aligned with the schematic representation of the 5-LTR. The complete
nucleotide sequence of the U3 region is shownwith the transcription factor binding sites indicated by arrows and all of the CpG dinucleotides shown in boxes.
me, methylated CpGs. DAS, downstream activating sequence.
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qPCR. As shown in Fig. 8B, we observed significant decreases
in DNMT1, DNMT3A and DNMT3B mRNA levels in
L267LtaxSN cells compared with L267 cells, whereas BLV
transcripts were more abundant in the productive
L267LtaxSN cells than in the silent L267 cells. These results
suggest that TaxBLV down-regulates DNMT expression at
the transcriptional level, which could, at least in part, explain
the lower level of DNA methylation we observed in the
L267LTaxSN 5-LTR compared with that observed in the L267
5-LTR.
On the basis of our results, we concluded thatTaxBLV-depen-
dent down-regulation of DNMT expression could lead to a
lower level of DNA methylation in the BLV promoter region,
notably in the CRE site region. The transcription factors CREB/
CREM/ATF-1 could subsequently bind to their cognate sites
and allowTaxBLV-mediated transactivation of the BLV 5-LTR,
thereby facilitating virus escape from latency.
DISCUSSION
BLV proviral latency appears to represent a viral strategy to
escape host immune system and allow tumor development.
Our laboratory had previously demonstrated the role of histone
deacetylation inBLV transcriptional repression (26–29). In this
report, we further studied the epigenetic control of BLV expres-
sion and showed that BLV promoter activity was induced by
several DNAmethylation inhibitors (such as 5-AZAdc). More-
over, ectopically expressed DNMT1 and DNMT3A, but not
DNMT3B, down-regulated BLV promoter activity. However,
we failed to detect any recruitment in vivo of DNMTs to the
FIGURE6. InhibitionofCREB/CREM/ATF-1 transcription factorbindingby
methylation at the154 and129 CpGs. A, EMSA analysis of nuclear fac-
tors interacting with the methylated or unmethylated TxRE1 probes. The
nucleotide sequence of the methylated TxRE1–154me double-stranded oli-
gonucleotide is shownwith theCRE1 site indicatedbyanarrowon the coding
strand and with themethylated cytosine residues indicated by the abbrevia-
tion me. The unmethylated TxRE1 double-stranded oligonucleotide (lanes 1–5)
or its methylated version, TxRE1–154me (lanes 6–10), was used as probe and
incubated with nuclear extracts from the BLV latently infected B-cell line L267
(30 g) treated (lanes 2 and 7) or not (lanes 1 and 6) with PMA ionomycin
(PI) for 30min, from thedefective cell line YR2 (15g) treated (lanes 4 and 9)
or not (lanes 3 and 8) with PMA  ionomycin, or from BLV-infected ovine
PBMCs (10g) (lanes 5 and 10). Sequence-specific retarded bands of interest
are shown. A minor and two major protein-DNA complexes were observed
and named C1, C2, and C3, respectively (indicated by arrows). The presence
of ATF-2 in the minor protein-DNA complex C1 and the presence of ATF-1,
CREB, and CREM in the major protein-DNA complex C2 were reported previ-
ously by our laboratory (17). B, EMSA analysis of nuclear factors interacting
with the methylated or unmethylated TxRE2 probes. The nucleotide
sequence of themethylated TxRE2–129medouble-stranded oligonucleotide
is shown with the CRE2 site indicated by an arrow on the coding strand and
with themethylated cytosine residues indicated by the abbreviationme. The
unmethylated TxRE2 double-stranded oligonucleotide (lanes 1–5) or its
methylated version, TxRE2–129me (lanes 6–10), was used as probe and incu-
batedwithnuclearextracts fromtheBLV latently infectedB-cell lineL267 (30g)
treated (lanes 2 and 7) or not (lanes 1 and 6) with PMA ionomycin for 30 min;
from the defective cell line YR2 (15g) treated (lanes 4 and 9) or not (lanes 3 and
8)withPMA ionomycin;or fromBLV-infectedovinePBMCs (10g) (lanes5and
10). Sequence-specific retarded bands of interest are shown. A minor and two
major protein-DNA complexeswere observed (C1, C2, and C3, respectively; indi-
cated by arrows). The presence of ATF-2 in the minor protein-DNA complex C1
and the presence of ATF-1, CREB, and CREM in themajor protein-DNA complex
C2 were reported previously by our laboratory (17). C, CREB/CREM/ATF-1 are
recruited in vivo to the BLV 5-LTR CRE region. YR2 and L267 cells were cross-
linked for 10 min at room temperature with 1% formaldehyde. To detect chro-
mosomal flanking regions,pelletswere sonicated toobtainDNAfragmentsof an
average size of 400 bp. Chromatin immunoprecipitations were performed with
anantibodydirected against CREB, CREM,ATF-1, or ATF-2. To test aspecific bind-
ing to the beads, a purified IgG was used as a control for immunoprecipitation.
QuantitativePCRreactionswereperformedwitholigonucleotideprimershybrid-
izing ina regionoverlappingthe threeCREsitesof theBLVLTRor in theU5region
of the BLV LTR, where no CRE binding site has been reported previously. -Fold
enrichments were calculated as the percentage of input values following the
formula: Immunoprecipitated DNA (IP)/total DNA (IN). Values represent the
means of triplicate samples S.E. An experiment representative of three inde-
pendent ChIP assays is shown.
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BLV promoter neither in the context of transiently transfected
LTR-luc reporter constructs nor in the latently infected cell
lines YR2 and L267. It should be stressed that several viral pro-
moters have been shown to be regulated by CpG methylation
(54–57), but in vivo DNMT recruitment to these viral regions
has never been reported so far. This could be explained by a
rapid kinetics of DNMT action or by a transient and/or weak
recruitment of these enzymes to the viral promoters.
Importantly, using the sodium bisulfite sequencing tech-
nique, we showed that DNA cytosine hypermethylation in the
5-LTR U3 and R regions of the integrated proviral DNA was
associated with a BLV true latency state in the lymphoma-de-
rived B-cell line L267 but not with a defective latency state in
the YR2 cell line. Indeed, the YR2 cell line is a B-cell line char-
acterized by a silent defective TaxBLV-mutated provirus (33,
36), whereas the L267 cell line is a transformed B-cell clone
isolated from a lymphomatous BLV-infected sheep, which car-
ries a single full-length, nondefective, transcriptionally silent
provirus (36, 37). This latter cell line represents a true latency
state, i.e. a reversible, transcriptionally silent, but replication-
competent provirus. These results suggest that BLV gene
expression is inactivated in tumoral cells by epigenetic mecha-
nisms such as DNA methylation or by genetic alterations such
as inactivating mutations in the tax gene.
FIGURE 7. Down-regulation of BLV promoter activity by site-specific
methylation. A, using site-directed mutagenesis we generated BLV pro-
moter luciferase constructs with site-specific methylation at the 154 CpG
or/and129CpG (pLTR-154me, pLTR-129me, andpLTR-154/-129me, respec-
tively) aswell as its unmethylated counterpart, pLTRwt-luc. By the same tech-
nique, we generatedmutated BLV promoter luciferase constructs containing
point mutation abolishing transcription factor binding to the CRE1 or CRE2
motif (pLTRmutCRE1 or pLTRmutCRE2, respectively). The products from
these mutagenesis reactions (500 ng of DNA) were transfected directly into
HeLa cells using the FuGENE procedure. Each transfection included 50 ng of
the internal control plasmid, pRL-TK, in which the herpes simplex virus thy-
midine kinase promoter drives Renilla luciferase gene expression. Luciferase
activities (firefly and Renilla) weremeasured in cell lysates 44 h after transfec-
tion. The results are expressed as luciferasefirefly/luciferaseRenilla. As an addi-
tional control, we generated a pLTRwt-luc derivative that was hypermethyl-
ated only in the LTR (i.e. in which every CpG of the BLV LTR, but no CpG
elsewhere in the pLTRwt-luc plasmid, wasmethylated in vitro by SssI methyl-
transferase) and named pLTRmSssIme. The results are presented as histo-
grams indicating the luciferase activity of each reporter construct relative to
that measured with the pLTRwt-luc vector, which was arbitrarily assigned an
activity value of 100%. The down-regulation of BLV promoter activity by
methylation(s) or by mutation(s) is also indicated (-fold) at the top of the
histogram representation. Means S.E. from five independent transfections
performed with different DNA products are shown. B, HeLa cells were tran-
siently cotransfectedusing the FuGENEprocedurewith 500ngof pLTRwt-luc,
pLTRmutCRE1, or pLTRmutCRE2 and 50 ng of the internal control plasmid,
pRL-TK.Here, in contrast to theplasmidsused inA, the reporterplasmidswere
amplified in bacteria prior to transfection. Luciferase activities (firefly and
Renilla) were measured in cell lysates 44 h after transfection. The results are
expressed as Luciferasefirefly/luciferaseRenilla. The results are presented as his-
tograms indicating the luciferase activity of each reporter construct relative
to thatmeasuredwith thepLTRwt-luc vector,whichwas arbitrarily assigned a
value of 100% of activity. The down-regulation of BLV promoter activity by
mutations is indicated (in -fold) at the top of the histogram representation.
Means S.E. from triplicate samples are represented. An experiment repre-
sentative of two independent transfections is shown.
FIGURE 8. Down-regulation of DNMT expression levels by TaxBLV.
A, nuclear extracts from the two BLV-infected cell lines, L267 and L267LTaxSN,
were analyzed by Western blotting with an antibody directed against
DNMT1, DNMT3B, or DNMT3A. We could not assess the protein level of
DNMT3A because no ovine antibody against DNMT3A was available com-
mercially, and the murine anti-DNMT3A antibody did not reveal any specific
band in either the L267 or the L267LTaxSN cellular extracts. B, total RNA sam-
ples were extracted from L267 or L267LTaxSN cells and digested by DNase I.
First strand cDNA was synthesized by reverse transcription, and qPCR reac-
tions were performed with oligonucleotide primers amplifying DNMT1,
DNMT3A, or DNMT3B transcripts and -actin transcripts. The results are
presented as the ratio of DNMT to -actin. Means  S.E. from triplicate
samples are represented. An experiment representative of three inde-
pendent experiments is shown. As a control, we performed quantitative
PCR with oligonucleotide primers amplifying the 5-UTR region of the BLV
as presented in Fig. 2A.
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Efficient BLV transcription requires the virus-encoded
TaxBLV protein, which acts through three TxREs located in the
5-LTR. The binding of CREB, CREM, and ATF transcription
factors to the three imperfect CRE sites located in each TxRE
has been proposed to allow TaxBLV-mediated transcriptional
activation. In this report, we showed that DNA methylation
inhibitors synergistically enhanced the transcriptional activa-
tion of the BLV promoter by TaxBLV in a CRE-dependent man-
ner. Mechanistically, methylation of the CpG located at the
154 position or at the129 position relative to the transcrip-
tion start site impairs in vitro CREB/CREM/ATF-1 transcrip-
tion factor binding to the distal CRE1 or middle CRE2 site,
respectively. Moreover, methylation at the 129 CpG alone
was sufficient to decrease by 2-fold BLV promoter-driven
reporter gene expression. By ChIP experiments, we demon-
strated in vivo the recruitment of the transcription factors
CREB and CREM, and to a lesser extent ATF-1, to the hypo-
methylated CRE region of the YR2 5-LTR, whereas we
detected no CREB/CREM/ATF recruitment to the hyperm-
ethylated corresponding region in the L267 cell line, thereby
indicating an inverse correlation between hypermethylation of,
and in vivo CREM/CREM/ATF-1 binding to, the BLV pro-
moter. As TaxBLV recruitment to the BLV LTR requires CREB/
CREM/ATF binding to the TxREs, CpG methylation also
impairs TaxBLV-mediated transactivation (see above). These
findings suggest that site-specific DNAmethylation of the BLV
promoter represses viral transcription by directly inhibiting
transcription factor binding and that CpG methylation con-
tributes to true proviral latency, together with histone
deacetylation.
The methylation status of the 5-LTR of BLV has been con-
troversial so far. Indeed, an earlier study using methylation-
sensitive restriction enzymes has shown that the proviral DNA
is hypermethylated in BLV-induced tumors (58). Later on,
another study reported by Tajima et al. (59) examined the
extent of DNA methylation of the U3 region and part of the R
region of the 5-LTR in BLV-infected cattle and in experimen-
tally BLV-infected sheep at various stages of the disease; and
they detected no or minimal CpG methylation of the U3/R
region by the bisulfite genomic sequencing method even in
tumor cells. The first study (58) is in agreement with our results
in the true latent L267 cell line, whereas the second study (59)
seemsmore compatible with what we observed in the defective
latent YR2 cell line. Therefore, a possible explanation for these
discrepancies could be that the tumor cells examined in Taji-
ma’s study carried proviruses silenced by genetic alteration(s),
such as deletions in the BLV provirus or mutations into func-
tionally important domains of the TaxBLV protein, that are well
established mechanisms of transformation-associated virus
silencing in ovine B-cell tumors (10, 36, 60).
We also studied the BLV 5-LTR methylation status in the
L267LTaxSN cell line in which expression of TaxBLV via the
pLTaxSN vector relieves the repressive state of the L267 provi-
rus and allows viral expression, as shown by viral RNA expres-
sion and by virus release in the naive host (34). In this produc-
tive L267LTaxSN cell line, the U3 region is almost completely
devoid of methylated CpGs, and the 5-half of the R region is
methylated but to a lesser extent compared with the L267 cell
line. These results reinforce the inverse correlation between the
degree of methylation of cytosine residues at CpG dinucleoti-
des in proviral DNA and the transcriptional activity of the BLV
promoter.
Importantly, our results indicate that TaxBLV expression
decreases DNMT1, DNMT3A, and DNMT3B expression lev-
els, which could explain, at least in part, the lower level of DNA
methylation observed in the L267LTaxSN 5-LTRcomparedwith
the L267 5-LTR. In addition to playing a direct tumorigenic
function, TaxBLV and its more extensively studied HTLV-1
counterpart TaxHTLV-1 modulate the expression of several
genes, either up- or down-regulating their expression through
mechanisms including Tax interaction with cellular transcrip-
tion factors, chromatin-modifying enzymes, and proteins
involved in the posttranscriptional control of mRNA expres-
sion (61). Selective down-regulation of gene expression by
TaxBLVmay result from its interaction withmethyl-CpG-bind-
ing domain 2 demethylase (MBD2), with histone methyltrans-
ferase Suv39h1, and/or with HDACs, interactions already
reported for TaxHTLV-1 (Ref. 62–64 and our laboratory).13 Pro-
teins from other oncogenic viruses have been shown to disturb
the host-DNA methylation system by up-regulating DNMT
expression, thereby maintaining hypermethylation of tumor
suppressor genes (64–66). Here, we show that TaxBLV down-
regulates DNMT expression, which leads to a lower level of
methylation in the BLV promoter region and contributes to
virus escape from latency.
Despite their similar sequences, the 5-LTR contains the
transcriptional promoter, whereas the 3-LTR has a poly-
adenylation function. In this report, we also have shown the
hypomethylated status of the 3-LTR by bisulfite genomic
sequencing analysis of the proviruses integrated in the three
BLV-infected cell lines (YR2, L267, andL267LTaxSN), revealing a
different methylation pattern of the 3-LTR compared with the
5-LTR. Such a differential level of methylation between the
two LTRs has already been reported for the HTLV-I virus,
where the 5-LTR and the 3-LTR are hypermethylated and not
methylated at all, respectively, in the same population of adult
T-cell leukemia cells (67–70). The unmethylated state of the
HTLV-I 3-LTR is consistent with its transcriptionally active
role in promoting the expression of the HTLV-I bZIP (HBZ)
gene, which is important for the proliferation of adult T-cell
leukemia- and HTLV-I-infected cells and is encoded by the
minus strand of the provirus (71).
Mechanistically, we have shown that CpGmethylation in the
BLV 5-LTR impairs in vitro and in vivo CREB/CREM/ATF-1
binding to their cognate sites in the U3 region. Furthermore,
CpG methylation at the 129 position alone was sufficient to
reduce by 2-fold the BLV LTR-driven luciferase expression in
our transient transfection experiments. The literature has
reported a few examples of such transcriptional repression by
direct inhibition of factor binding by site-specific methylation,
such as for themouse Bdnf (brain-derived neurotrophic factor)
gene (44) or the interferon- gene (72). In addition to directly
prevent the binding of transcription factors to their cognate
13 C. Van Lint, unpublished results.
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binding sites, CpG methylation could also act through attach-
ment of methyl-CpG-binding proteins, which in turn recruit
repressive chromatin modification enzymatic complexes.
Moreover, inhibition of CREB/CREM/ATF-1 binding im-
pairs TaxBLV-mediated transcriptional activation of the BLV
promoter (as strongly suggested by the fact that DNA methyl-
ation inhibitors and TaxBLV synergistically activated BLV gene
expression in a CRE-dependent manner). This binding inhibi-
tion could also impair the recruitment of the histone acetyl-
transferase coactivators CREB-binding protein (CBP)/p300;
their role in BLV transcriptional regulation, recently demon-
strated by our laboratory (17), leads to a reduction in the level of
histone acetylation, reinforcing the transcriptionally silenced
state of integrated BLV proviruses.
In conclusion, our results constitute direct evidence for an
interplay between the DNA methylation status of, and CREB/
CREM/ATF protein binding to, the BLV promoter, a mecha-
nism that could contribute to true proviral latency. Together
with previous data on the role of chromatin modifications in
BLV expression, the present work contributes to a deeper
understanding of the complex epigenetic control of BLV tran-
scriptional latency.
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